ASCO 2024: Merus touts positive Phase II data for head and neck cancer antibody
Shares in Merus rose by 15% in premarket trading, following the announcement of positive Phase II data to be presented at ASCO.
Shares in Merus rose by 15% in premarket trading, following the announcement of positive Phase II data to be presented at ASCO.
What's Your Reaction?
